Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810405 | 0.81 | MEN1 (0.60) | MAPTALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL4442716 | 0.74 | HSD17B1 (0.56) | MAPTALDH1A1KDM4EGAAHDAC3 | |
| SCHEMBL978331 | 0.74 | GAA (0.49) | MAPTALDH1A1KDM4EGAAHDAC3 | |
| SCHEMBL7557552 | 0.74 | CYP1A2 (0.56) | MAPTALDH1A1KDM4EGAAHDAC3 | |
| SCHEMBL11645477 | 0.74 | POLB (0.52) | MAPTALDH1A1GAAHDAC3KMT2A | |
| SCHEMBL11388056 | 0.71 | LMNA (0.47) | MAPTALDH1A1ERAP2LNPEPNPC1 | |
| SCHEMBL25460707 | 0.70 | MTNR1B (0.55) | MAPTALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL17934114 | 0.70 | ALDH1A1 (0.64) | MAPTALDH1A1KDM4EGAANPC1 | |
| SCHEMBL12199660 | 0.70 | ALDH1A1 (0.52) | MAPTALDH1A1GAAHDAC3HDAC1 | |
| SCHEMBL763435 | 0.70 | ALDH1A1 (0.44) | MAPTALDH1A1KDM4EHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300276-A1 | Heterocyclic Carboxylic Acide Amide Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-12-04 | — | — | US | disclosed |
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MAPT 3394/4885ALDH1A1 3399/4885KDM4E 934/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MAPT 3498/4885ALDH1A1 3195/4885KDM4E 1346/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MAPT 3025/4885ALDH1A1 3627/4885KDM4E 1242/4885 |
| US-20080300276-A1 | Heterocyclic Carboxylic Acide Amide Derivatives | HCAR2, GRIN1, HCAR1 | MAPT 3812/4885ALDH1A1 1955/4885KDM4E 1258/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | MAPT 3477/4885ALDH1A1 3307/4885KDM4E 885/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | MAPT 4133/4885ALDH1A1 1852/4885KDM4E 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.